NCT06440980

A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight

A Multiple-Dose Study to Investigate the Bioequivalence of Orforglipron (LY3502970) Capsules and Orforglipron Tablets in Participants With Obesity or Overweight Who Are Otherwise Healthy.

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 533 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The main purpose of this study is to see how much of orforglipron (study drug) gets into the bloodstream and how long it takes the body to get rid of it when given as capsules compared to tablets in healthy overweight and obese participants. The safety and tolerability (side effects) of orforglipron when given as capsules and tablets will also be evaluated. The study will be conducted in two parts, with part A and B lasting up to approximately 25 and 22 weeks each respectively, including the screening period.

Conditions

• Healthy
• Obese
• Overweight
• Obesity

Interventions

Type	Name	Description
DRUG	Orforglipron	Administered orally

Timeline

• Start date: 2024-06-24
• Primary completion: 2025-06-02
• Completion: 2025-06-02
• First posted: 2024-06-04
• Last updated: 2025-06-24

Locations

7 sites across 1 country: United States

Regulatory

• FDA-regulated drug study